Abstract
Mass vaccination offers the best strategy to fight against COVID-19 pandemic, and SARS-CoV2 vaccines are being approved in several countries for emergency use. In Brazil, vaccine approval is expected in the next few days, however potential concerns exist regarding vaccine recommendations for specific populations, such as patients with inflammatory bowel disease (IBD). To address these questions, the Brazilian IBD Study Group (GEDIIB) provides this practical advice with key recommendations about the COVID-19 vaccines in IBD population.
Cite
CITATION STYLE
Queiroz, N. S. F., Teixeira, F. V., Freire, C. C. F., Motta, M. P., De Vasconcellos, M. A. M., Chebli, L. A., & Hossne, R. S. (2021). Brazilian ibd study group position statement on sars-cov2 vaccination. Arquivos de Gastroenterologia, 58(1), 2–4. https://doi.org/10.1590/s0004-2803.202100000-02
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
